Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

e company reiterated its 2009 financial guidance for revenue and operating expenses initially provided on February 26, 2009.

Revenue

Revenue for 2009, including Actimmune(R) and anticipated milestone payments from Roche, is expected to be in a range of approximately $40 to $50 million. Actimmune revenue represents approximately 50% of this revenue range.

Operating Expenses

R&D expense is anticipated to be in a range of approximately $90 to $100 million, net of development cost reimbursements under the Roche collaboration. Of this amount, approximately 60% is attributed to pirfenidone which includes expenses for CAPACITY, RECAP, the preparation and support of NDA and MAA submissions and manufacturing.

Approximately 35% of the R&D expense is attributed to the company's one-third share of all development expenses incurred by the collaboration with Roche on ITMN-191. The balance of 2009 R&D expense is related to the advancement of a named pirfenidone analog compound, ITMN-520, toward an expected IND filing in mid-2010.

G&A expense is anticipated to be in a range of approximately $35 to $40 million. The G&A guidance range includes approximately $5.0 million of various pirfenidone pre-marketing costs and a similar amount in legal fees associated with a DOJ action against a former InterMune executive covered by an indemnification agreement.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EDT to discuss its financial results for the first quarter 2009, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 95970767. A replay of the webcast and teleconference will be available approximately three hours
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... Pa., Dec. 1 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... announced,that the company will attend the 20th Annual Piper ... The 20th Annual Piper Jaffray Health Care Conference ... December 3, 2008, at the New York,Palace Hotel in ...
... Tigermed Consulting Co., Ltd,a leading Contract Research ... has,established a subsidiary, Hunan Tigermed Xiangya Drug ... (CSU). The establishment of Tigermed Xiangya ... nationwide first-rate Phase,I Clinical Laboratory, and further ...
... COPENHAGEN, December 1 A strong pipeline makes the,Copenhagen Region ... candidates in preclinical and clinical development, Denmark,ranks third in Europe. ... Also in term of ... largest pipeline growth among the countries in Europe. , ...
Cached Biology Technology:Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya) 2Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe 2
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Even bird brains can get to know an entire continent ... do so, suggests a Princeton research team. The ... way to their winter nesting grounds even after being thrown ... to compensate for the displacement. However, similarly displaced juvenile birds, ...
... today its involvement in an expanded access program ... for phenylketonuria (PKU), a rare genetic metabolic disorder ... can result in severe mental retardation. Currently, there ... program at Nationwide Childrens. Under an expanded ...
... at the Wildlife Conservation Society and other institutions declare ... in South Asia could double the number of tigers ... The study appears in the most recent edition ... examined 157 reserves throughout the Indian subcontinentcomprising India, Bangladesh, ...
Cached Biology News:For migrating sparrows, kids have a compass, but adults have the map 2Nationwide Children's Hospital involved in expanded access program for treatment of PKU 2WCS study finds potential to double tiger numbers in South Asia 2
... to Peroxiredoxin 1 Peroxiredoxin (Prx) ... mammalian members have been known to ... apoptosis. Many isoforms (about 50 proteins), ... acid sequence homology, particularly amino-terminal region ...
... Heat activated ,• Eliminates nonspecific products ... Excellent specificity allows extension through DNA ... ,• Leaves an 'A' overhang ... of GeneChoice DNA Polymerase that remains ...
... beta Synuclein Synucleins are small, soluble ... in certain tumors. The family includes three ... gamma synuclein. The alpha and beta synuclein ... where they are seen mainly in presynaptic ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: